Pursuant to article 228 of the consolidated text of the Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October and to article 17 of Regulation (EU) n°596/2014 on market abuse, Pharma Mar, S.A. ("Pharma Mar" or the "Company") hereby discloses the following

**REGULATORY ANNOUNCEMENT**

On the date hereof, Pharma Mar has entered into a licensing and marketing agreement with Singapore-based Specialised Therapeutics Asia Pte Ltd ("STA") to market the marine-based anti-tumour compound of the Company, lurbinectedin (PM1183) for the treatment of platinum-resistant ovarian cancer, small-cell lung cancer, BRCA 1/2-associated metastatic breast cancer and other future oncology indications in Australia, New Zealand and in 12 Asian countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Papua New Guinea, Philippines, Singapore, Timor-Leste, Thailand and Vietnam) (the "Licensing Agreement").

Under the terms of the Licensing Agreement, Pharma Mar will receive an upfront payment followed by remunerations upon achieving regulatory and sales milestones with lurbinectedin. Pharma Mar will retain exclusive production rights and will supply the finished dosage form to STA.

In addition, in accordance with the Licensing Agreement, Pharma Mar, STA and Specialised Therapeutics Investments Pty LTD ATF The Specialised Therapeutics Unit Trust ("STA Trust"), an entity controlled by STA have entered into on the date hereof into a subscription agreement, whereby STA Trust has undertaken to subscribe 444,400 new common stock of Pharma Mar, representing 0.2% of its share capital, at a subscription price per share of €4.75 (€0.05 nominal value plus €4.70 share premium), equal to 130% over the simple average of the daily weighted average market prices of the shares of Pharma Mar during the 20 trading days prior to the signing of the Licensing Agreement (the "Subscription Agreement"). Therefore, the total amount of the share capital increase (nominal value and share premium) will be €2,110,900, corresponding €22,220 to nominal amount and €2,088,860 to share premium (the "Share Capital Increase").

The Licensing Agreement will become effective on the date of the granting of the Spanish public deed in connection with the Share Capital Increase, which is expected to occur in the following days. The Company will request the admission to trading of the new shares in the Madrid, Barcelona, Bilbao and Valencia stock exchanges.

The Share Capital Increase has the sole purpose of introducing STA in the share capital of the Company, in the context of the industrial and business collaboration agreements entered into by
both companies. The Share Capital Increase intends to reinforce this relationship by creating a permanent and stable relationship in the long term and aligning the interests of the parties. STA Trust has agreed to a 2-year lock-up in respect of 50% of the shares and to a 4-year lock-up in respect of the remaining 50% of the shares.

The Board of Directors of the Company has approved on the date hereof the terms of the Licensing Agreement and the Subscription Agreement and has agreed to carry out the Share Capital Increase pursuant to the delegation conferred by the General Shareholders’ Meeting of the Company dated 30 June 2015 (Zeltia, S.A.’s decision as sole shareholder of the Company at that time). The Board of Directors has also approved the report on the Share Capital Increase with exclusion of the pre-emptive rights of the current shareholders, in accordance with articles 286, 308, 504 and 506 of the consolidated Spanish Companies Act, approved by Royal Legislative Decree 1/2010, of 2 July. The report from the Board of Directors, together with the report of Grant Thornton, S.L.P., in its condition as independent auditor appointed for these purposes by the Commercial Registry, will be made available to the shareholders and notified in the first General Shareholders’ Meeting of the Company held after the Share Capital Increase.

Attached hereto is the press release which will be distributed to the media on the date hereof.

In Colmenar Viejo (Madrid), on 17 May 2017
PharmaMar and Specialised Therapeutics Asia sign licensing and marketing agreement for lurbinectin covering Australia, New Zealand and several Asian countries

Madrid, 17 May 2017 – PharmaMar (MSE:PHM) today announced an agreement with Singapore-based Specialised Therapeutics Asia Pte, Ltd (STA) to market the marine-based anti-tumour compound of the Company, lurbinectin (PM1183) for the treatment of platinum-resistant ovarian cancer, small-cell lung cancer, BRCA 1/2 -associated metastatic breast cancer and other future oncology indications in Australia, New Zealand and in 12 Asian countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Papua New Guinea, Philippines, Singapore, Timor-Leste, Thailand and Vietnam).

Under the terms of this license agreement and a related subscription agreement, Specialised Therapeutics Investments Pty LTD ATF The Specialised Therapeutics Unit Trust (STA Trust), an entity controlled by STA, has undertaken to subscribe 444,400 new common stock of PharmaMar, representing 0,2% of PharmaMar´s share capital, at a subscription price per share of €4.75, equal to a 30% premium over the volume weighted average market price of the shares of PharmaMar on the Spanish Stock Exchanges during the 20 trading days prior to the signing of the licence agreement. Therefore, the total subscription amount (nominal value and share premium) of the share capital increase of PharmaMar will be €2,110,900, corresponding €22,220 to nominal amount and €2,088,680 to share premium. STA Trust has agreed to a 2 years lock-up in respect of 50% of the shares and to a 4 years lock-up in respect of the remaining 50% of the shares.

In addition, PharmaMar will receive an upfront payment followed by remunerations upon achieving regulatory and sales milestones with lurbinectin. PharmaMar will retain exclusive production rights and will supply the Finished Dosage Form to STA.
Lurbinectedin (PM1183), the third anti-tumour compound to be developed by PharmaMar from a marine organism, is currently undergoing development for the treatment of solid tumours. This promising agent is currently in final stage (Phase 3) trials as a potential new therapy for various solid tumours, including platinum-resistant ovarian cancer and small cell lung cancer. In addition, it is in Phase 2 trial for BRCA1 and BRCA2 associated metastatic breast cancer.

José María Fernández Sousa-Faro, Chairman of PharmaMar, commented, “we are about to address our second strategic alliance with STA for the commercialization of a marine-based cancer drug. Lurbinectedin has shown antitumoral activity in several solid tumors. We shall continue with the clinical development of the molecule and to advance in the upcoming regulatory steps to obtain its approval in the years to come”.

Carlo Montagner, CEO of Specialised Therapeutics Asia, said this new licensing deal cemented the company’s existing strong relationship with PharmaMar and demonstrated high confidence in the partner company’s development pipeline. “We have the highest regard for PharmaMar and are pleased to partner once again, pursuing development of this highly promising oncology compound”, he said. “We eagerly await data from these final stage studies and look forward to making new therapies like this available to patients throughout our regions who are affected by difficult to treat cancers”.

About PM1183 (lurbinectedin)

PM1183 is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction. The antitumor efficacy of lurbinectedin is being investigated in various types of solid tumors.

About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other three clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM60184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Austria, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain’s leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova zeltia and Xylazel. To learn more about PharmaMar, please visit us at www.pharmamar.com.
About Specialised Therapeutics Asia

Specialised Therapeutics Asia Pte Ltd (ST Asia) is an international biopharmaceutical company established to provide pioneering healthcare solutions to patients throughout South East Asia, as well as in Australia and New Zealand. The company is a close affiliate of Specialised Therapeutics Australia (STA), which also collaborates with leading global pharmaceutical and diagnostic companies to bring novel, innovative and life changing healthcare solutions to patients affected by a range of diseases. ST Asia is committed to making new and novel therapies available to patients around the world, with a broad therapeutic portfolio spanning oncology, hematology, urology and ophthalmology. Additional information can be found at www.STAbiopharma.com

Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: + 34609493127
Paula Fernández – Media Relations Manager pfalarcon@pharmamar.com Mobile: +34 638796215
Phone: +34 918466000

Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com

###